Measuring psoriatic disease in clinical practice. An expert opinion position paper

Autoimmunity Reviews

Volumn 14, Issue 10, 2015, Pages 864-874

  Lubrano, Ennio ^a   Cantini, Fabrizio ^b   Costanzo, Antonio ^c   Girolomoni, Giampiero ^d   Prignano, Francesca ^e   Olivieri, Ignazio ^f   Scarpa, Raffaele ^g   Spadaro, Antonio ^c   Atzeni, Fabiola ^h   Narcisi, Alessandra ^c   Ricceri, Federica ^e   Sarzi Puttini, Piercarlo ^h  

^a UNIVERSITY OF MOLISE   (Italy)

^b AUSL 4   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f San Carlo Hospital of Potenza   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular; Comorbidities; Metabolic syndrome; Outcome measures; Psoriasis; Psoriatic arthritis

Indexed keywords

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ANXIETY DISORDER; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMORBIDITY; CROHN DISEASE; DACTYLITIS; DEPRESSION; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE SEVERITY; DYSLIPIDEMIA; ENTHESITIS; FIBROMYALGIA; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NAIL PSORIASIS SEVERITY INDEX; NONALCOHOLIC FATTY LIVER; OBESITY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE; REVIEW; SKIN DISEASE ASSESSMENT; ULCERATIVE COLITIS; UVEITIS; COMPLICATION; QUALITY OF LIFE; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; OBESITY; PSORIASIS; QUALITY OF LIFE; RISK FACTORS;

EID: 84940614895     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.05.010     Document Type: Review

References (143)

1. Davidovici B.B., Sattar N., Prinz J., Puig L., Emery P., Barker J.N., et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Investig Dermatol 2010, 130:1785-1796.
2. Mease P.J., Gladman D.D., Papp K.A., Khraishi M.M., Thaçi D., Behrens F., et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013, 69:729-735.
3. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007, 157:68-73.
4. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013, 68:654-662.
5. Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009, 51:758-764.
6. Mehta N.N., Yu Y., Pinnelas R., Krishnamoorthy P., Shin D.B., Troxel A.B., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011, 124(775):e1-e6.
7. Ahlehoff O., Gislason G.H., Charlot M., Jørgensen C.H., Lindhardsen J., Olesen J.B., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011, 270:147-157.
8. Samarasekera E.J., Neilson J.M., Warren R.B., Parnham J., Smith C.H. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Investig Dermatol 2013, 133:2340-2346.
9. Strohal R., Kirby B., Puig L., Psoriasis Expert Panel, Girolomoni G., Kragballe K., et al. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2014, 28:1661-1669.
10. Scarpa R., Ayala F., Caporaso N., Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease?. J Rheumatol 2006, 33:210-212.
11. Puzenat E., Bronsard V., Prey S., Gourraud P.A., Aractingi S., Bagot M., et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010, 24(Suppl. 2):10-16.
12. Augustin M., Blome C., Costanzo A., Dauden E., Ferrandiz C., Girolomoni G., et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol 2014, 170:591-598.
13. Mease P.J. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011, 11(63 Suppl):S64-S85.
14. Boehncke W.H., Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol 2013, 14:377-388.
15. Naldi L., Svensson A., Diepgen T., Elsner P., Grob J.J., Coenraads P.J., et al. Randomized clinical trial for psoriasis 1877-2000: the Eden survey. J Investig Dermatol 2003, 120(5):738-741.
16. Bronsard V., Paul C., Prey S., Puzenat E., Gourraud P.A., Aractingi S., et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010, 24:17-22.
17. Martins G.A., Arruda L., Mugnaini A.S.B. Validation of life quality questionnaires for psoriasis patients. An Bras Dermatol 2004, 79:521-535.
18. Rich P., Scher R.K. Nail Psoriasis Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003, 49:206-212.
19. Schmitt J., Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005, 210:194-199.
20. Puzenat E., Bronsard V., Prey S., Gourraud P.A., Aractingi S., Bagot M., et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010, 24:10-16.
21. Garzitto A., Ricceri F., Tripo L., Pescitelli L., Prignano F. Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score. J Am Acad Dermatol 2013, 69:1053-1054.
22. NICE Psoriasis - the assessment and management of psoriasis October, (last accessed: April 24, 2015). http://www.nice.org.uk/guidance/cg153/resources/guidance-psoriasis-pdf.
23. Augustin M., Ogilvie A. Methods of outcomes measurement in nail psoriasis. Dermatology 2010, 221:23-28.
24. Lubrano E., Scrivo R., Cantini F., Marchesoni A., Mathieu A., Olivieri I., et al. Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists?. Arthritis Care Res (Hoboken) 2012, 64:455-458.
25. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
26. Garduno J., Bhosle M.J., Balkrishna R., Feldaman S.R. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatolog Treat 2007, 18:223-242.
27. Basra M.K., Fenech R., Gatt R.M., Salek M.S., Finlay A.Y. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008, 159:997-1035.
28. Gladman D.D., Mease P.J., Healy P., Helliwell P.S., Fitzgerald O., Cauli A., et al. Outcome measures in psoriatic arthritis. J Rheumatol 2007, 34:1159-1166.
29. Taylor W.J., Zmierczak H.G., Helliwell P.S. Problems with the definition of axial and peripheral patterns in psoriatic arthritis. J Rheumatol 2005, 32:974-978.
30. Gladmann D.D., Mease P.J., Strand V., Healy P., Helliwell P., Fitzgerald O., et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007, 34:1167-1170.
31. Lubrano E., Spadaro A. Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?. Clin Rheumatol 2012, 31:1027-1032.
32. Lubrano di Scorpaniello E., Spadaro A. Unmet needs in outcome measures of psoriatic arthritis: focus on axial radiographic and nail involvement. Acta Biomed 2013, 84:87-93.
33. Gladman D.D. Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007, 9:455-460.
34. Helliwell P.S., FitzGerald O., Fransen J., Gladman D.D., Kreuger G.G., Callis-Duffin K., et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013, 72:986-991.
35. Eder L., Chandran V., Shen H., Cook R.J., Gladman D.D. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. Ann Rheum Dis 2010, 69:2160-2164.
36. MacKay K., Mack C., Brophy S., Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998, 41:2263-2270.
37. Creemers M.C.W., Franssen M.J.A.M., van't Hof M.A., Gribnau F.W.J., van de Putte L.B.A., van Riel P.L.C.M. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005, 64:127-129.
38. Lubrano E., Marchesoni A., Olivieri I., D'Angelo S., Spadaro A., Parsons W.J., et al. The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 2009, 27:977-980.
39. Lubrano E., Marchesoni A., Olivieri I., D'Angelo S., Spadaro A., Parsons W.J., et al. Psoriatic arthritis spondylitis radiology index: a modified index for radiological assessment of axial involvement in psoriatic arthritis. J Rheumatol 2009, 36:1006-1011.
40. Biagioni B.J., Gladman D.D., Cook R.J., Eder L., Wakhlu A., Shen H., et al. Reliability of radiographic scoring methods in axial psoriatic arthritis. Arthritis Care Res (Hoboken) 2014, 66:1417-1422.
41. Ritchlin C.T., Kavanaugh A., Gladman D.D., Mease P.J., Helliwell P., Boehncke W.H., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387-1394.
42. Gossec L., Smolen J.S., Gaujoux-Viala C., Ash Z., Marzo-Ortega H., van der Heijde D., et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71:4-12.
43. Salvarani C., Pipitone N., Marchesoni A., Cantini F., Cauli A., Lubrano E., et al. Italian Society for Rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011, 29(3 Suppl. 66):S28-S41.
44. Marsal S., Armadans-Gil L., Martinez M., Gallardo D., Ribera A., Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999, 38:332-337.
45. Taylor W.J., Zmierczac H.G., Helliwell P.S. Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J Rheumatol 2005, 32:974-977.
46. Cantini F., Niccoli L., Nannini C., Kaloudi O., Bertoni M., Cassarà E. Psoriatic arthritis: a systematic review. Int J Rheum Dis 2010, 13:300-317.
47. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
48. Gladman D.D., Mease P.J., Strand V., Healy P., Helliwell P.S., Fitzgerald O., et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007, 34:1167-1170.
49. Clegg D.O., Reda D.J., Mejias E., Cannon G.W., Weisman M.H., Taylor T., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996, 39:2013-2020.
50. Gladman D.D., Tom B.D., Mease P.J., Farewell V.T. Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal-the PsA joint activity index. J Rheumatol 2010, 37:2559-2565.
51. Prevoo M.L.L., Van't Hoff M.A., Kuper H.H., Van Leeuwen M.A., Van de Putte L.B.A., Van Riel P.L.C.M. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
52. Nell-Duxneuner V.P., Stamm T.A., Machold K.P., Pflugbeil S., Aletaha D., Smolen J.S. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010, 69:546-549.
53. Coates L.C., Fitzgerald O., Gladman D.D., McHugh N.J., Mease P., Strand V., et al. Reduced joint counts misclassify psoriatic arthritis patients with oligoarthritis and miss significant active disease. Arthritis Rheum 2013, 65:1504-1509.
54. FitzGerald O., Helliwell P., Mease P., Mumtaz A., Coates L., Pedersen R., et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 2012, 71:358-362.
55. Saber T.P., Fearon U., Veale D.J. Is remission a more realistic goal in psoriatic arthritis?. Adv Musculoskelet Disord 2011, 3:3-7.
56. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010, 69:48-53.
57. Coates L.C., Cook R., Lee K.A., Chandran V., Gladman D.D. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010, 62:970-976.
58. Coates L.C., Helliwell P.S. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010, 62:965-969.
59. Mease P.J., Heckaman M., Kary S., Kupper H. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013, 40:647-652.
60. van der Heijde D., Sharp J., Wassenberg S., Gladman D.D. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005, 64(Suppl. 2):ii61-ii64.
61. Gladman D.D., Farewell V.T., Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate risk model. J Rheumatol 1995, 22:675-679.
62. Gladman D.D., Tung Hing E.N.G., Schentag C.T., Cook R.J. Remission in psoriatic arthritis. J Rheumatol 2001, 28:1045-1048.
63. McHugh N.J., Balachrishnan C., Jones S.M. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003, 42:778-783.
64. Queiro-Silva R., Torre-Alonso J.C., Tinture-Eguren T., Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003, 62:68-70.
65. Kane D., Stafford L., Bresnihan B., Fitzgerald O. A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis. "DIP or not DIP revisited". Rheumatology (Oxford) 2003, 42:1469-1476.
66. Kane D., Stafford L., Bresnihan B., Fitzgerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42:1460-1468.
67. Bond S.J., Farewell V.T., Schentag C.T., Gladman D.D. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007, 66:370-376.
68. Gratacos J., Casado E., Real J., Torre-Alonso J.C. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007, 66:493-497.
69. Cantini F., Niccoli L., Nannini C., Cassarà E., Pasquetti P., Olivieri I., et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008, 47:872-876.
70. Saad A.A., Ashcroft D.M., Watson K.D., Symmons D.P., Noyce P.R., Hyrich K.L. BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:697-705.
71. Eder L., Chandran V., Ueng J., Bhella S., Lee K.A., Rahman P., et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford) 2010, 49:1361-1366.
72. Glintborg B., Østergaard M., Dreyer L., Krogh N.S., Tarp U., Hansen M.S., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63:382-390.
73. Simon P., Pfoehler C., Bergner R., Schreiber M., Pfreundschuh M., Assmann G. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 2012, 30:45-50.
74. Iervolino S., Di Minno M.N., Peluso R., Lofrano M., Russolillo A., Di Minno G., et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol 2012, 39:568-573.
75. Theander E., Husmark T., Alenius G.M., Larsson P.T., Teleman A., Geijer M., et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2014, 73:407-413.
76. McGonagle D., Lories R.I., Tan A.L., Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007, 56:2482-2491.
77. Gladman D.D., Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford) 2011, 50:25-31.
78. Mander M., Simpson J.M., Mclellan A., Walker D., Goodacre J.A., WcC Dick Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987, 46:197-202.
79. Heuft-Dorenbosch L., Spoorenberg A., van Tubergen A., Landewé R., van ver Tempel H., Mielants H., et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127-132.
80. Gladman D.D., Inman R.D., Cook R.J., Maksymowych W.P., Braun J., Davis J.C., et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007, 34:1740-1745.
81. Heuft-Dorenbosch L., Spoorenberg A., van Tubergen A., Landewé R., van ver Tempel H., Mielants H., et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127-132.
82. Kavanaugh A., Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the long-term extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol 2012, 89:90-93. [Suppl.].
83. Healy P.J., Helliwell P.S. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008, 59:686-691.
84. Mease P.J., Fleischmann R., Deodhar A.A., Wollenhaupt J., Khraishi M., Kielar D., et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014, 73:48-55.
85. Eder L., Jayakar J., Thavaneswaran A., Haddad A., Chandran V., Salonen D., et al. Is the MAdrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls?. J Rheumatol 2014, 41:466-472.
86. Balint P.V., Kane D., Wilson H., McInnes I.B., Sturrock R.D. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002, 61:905-910.
87. Ferguson E.G., Coates L.C. Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. Clin Exp Rheumatol 2014, 32(5 Suppl. 85):S113-S117.
88. Rose S., Toloza S., Bautista-Molano W., Helliwell P.S., GRAPPA Dactylitis Study Group Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol 2014, 41:2295-2300.
89. Tan A.L., Fukuba E., Halliday N.A., Tanner S.F., Emery P., McGonagle D. High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Ann Rheum Dis 2015, 74:185-189.
90. Healy P., Groves C., Chandramohan M., Helliwell P.S. MRI changes in psoriatic dactylitis - extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology (Oxford) 2008, 47:92-95.
91. Helliwell Ps, Firth J., Ibrahim G.H., Melsom Rd, Shah I., Turner D.E. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005, 32:1745-1750.
92. Ni C., Chiu M.W. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol 2014, 7:119-132.
93. Onumah N., Kircik L.H. Psoriasis and its comorbidities. J Drugs Dermatol 2012, 11:5-10.
94. Sarzi-Puttini P., Atzeni F. New biological treatments for psoriatic arthritis. Isr Med Assoc J 2014, 16:643-645.
95. Atzeni F., Boccassini L., Antivalle M., Salaffi F., Sarzi-Puttini P. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 2011, 70:712-714.
96. Atzeni F., Sarzi-Puttini P., Vena G.A. Resistant cases of psoriatic arthritis: how to manage them. J Rheumatol Suppl 2009, 83:73-75.
97. Atzeni F., Turiel M., Boccassini L., Sitia S., Tomasoni L., Battellino M., et al. Cardiovascular involvement in psoriatic arthritis. Reumatismo 2011, 63:148-154.
98. Atzeni F., Sarzi-Puttini P., Sitia S., Tomasoni L., Gianturco L., Battellino M., et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2011, 38:1661-1664.
99. Favarato M.H., Mease P., Gonçalves C.R., Gonçalves Saad C., Sampaio-Barros P.D., Goldenstein-Schainberg C. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol 2014, 32:182-187.
100. González-Gay M.A., González-Juanatey C., Llorca J., Castañeda S. The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis: comment on 'Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review' by Jamnistki et al. Ann Rheum Dis 2014, 73:e27.
101. Kimball A.B., Leonardi C., Stahle M., Gulliver W., Chevrier M., Fakharzadeh S., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014, 171:137-147.
102. Kimball A.B., Gladman D., Gelfand J.M., Gordon K., Horn E.J., Korman N.J., et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008, 58:1031-1042.
103. Strohal R., Kirby B., Puig L., the Psoriasis Expert Panel, Girolomoni G., Kragballe K., et al. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2014, 28:1661-1669.
104. Miller I.M., Ellervik C., Yazdanyar S., Jemec G.B. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013, 69:1014-1024.
105. Calamita A.B., Calamita Z., Braga J.C. Risk factors for cardiovascular disease in psoriasis: relation to inflammation assessed by the severity and duration of illness. Inflamm Allergy Drug Targets 2013, 12:385-390.
106. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013, 31:433-442.
107. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
108. Eder L., Thavaneswaran A., Chandran V., Cook R.J., Gladman D.D. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2015, 74:813-817.
109. Miller I.M., Ellervik C., Yazdanyar S., Jemec G.B. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013, 69:1014-1024.
110. Labitigan M., Bahče-Altuntas A., Kremer J.M., Reed G., Greenberg J.D., Jordan N., et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014, 66:600-607.
111. Herédi E., Csordás A., Clemens M., Adám B., Gáspár K., Törőcsik D., et al. The prevalence of obesity is increased in patients with late compared with early onset psoriasis. Ann Epidemiol 2013, 23:688-692.
112. Dubreuil M., Rho Y.H., Man A., Zhu Y., Zhang Y., Love T.J., et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 2014, 53:346-352.
113. Dreiher J., Freud T., Cohen A.D. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract 2013, 2013:580404.
114. Jones S.M., Harris C.P., Lloyd J., Stirling C.A., Reckless J.P., McHugh N.J. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000, 59:904-909.
115. Antoniou C., Dessinioti C., Katsambas A., Stratigos A.J. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 2007, 156:1090-1091.
116. Hahn B.H., Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28:69-75.
117. Stinco G., Piccirillo F., Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 2007, 157:1273-1274.
118. Ramonda R., Lo Nigro A., Modesti V., Nalotto L., Musacchio E., Iaccarino L., et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011, 10:773-778.
119. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
120. Pehlevan S., Yetkin D.O., Bahadir C., Goktay F., Pehlevan Y., Kayatas K., et al. Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2014, 12:43-48.
121. Lin Y.C., Dalal D., Churton S., Brennan D.M., Korman N.J., Kim E.S., et al. Relationship of metabolic syndrome and CIMT measures in patients with psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 2014, 66:97-103.
122. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007, 157:68-73.
123. van der Voort E.A., Koehler E.M., Dowlatshahi E.A., Hofman A., Stricker B.H., Janssen H.L., et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55years old or older: results from a population-based study. J Am Acad Dermatol 2014, 70:517-524.
124. Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009, 51:758-764.
125. Miele L., Vallone S., Cefalo C., La Torre G., Di Stasi C., Vecchio F.M., et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009, 51:778-786.
126. Madanagobalane S., Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012, 53:190-197.
127. Li W.Q., Han J.L., Chan A.T., Qureshi A.A. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013, 72:1200-1205.
128. Cohen R., Robinson D., Paramore C., Fraeman K., Renahan K., Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008, 14:738-743.
129. Ho P., Bruce I.N., Silman A., Symmons D., Newman B., Young H., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005, 52:3596-3602.
130. Niccoli L., Nannini C., Cassarà E., Kaloudi O., Susini M., Lenzetti I., et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis 2012, 15:414-418.
131. Queiro R., Torre J.C., Belzunegui J., González C., De Dios J.R., Unanue F., et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002, 31:264-270.
132. Paiva E.S., Macaluso D.C., Edwards A., Rosenbaum J.T. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 2000, 59:67-70.
133. Buskila D., Langevitz P., Gladman D.D., Urowitz S., Smythe H.A. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992, 19:1115-1119.
134. Marchesoni A., Atzeni F., Spadaro A., Lubrano E., Provenzano G., Cauli A., et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 2012, 39:849-855.
135. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990, 33:160-172.
136. Wolfe F., Clauw D.J., Fitzcharles M.A., Goldenberg D.L., Katz R.S., Mease P., et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010, 62:600-610.
137. McDonough E., Ayearst R., Eder L., Chandran V., Rosen C.F., Thavaneswaran A., et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014, 41:887-896.
138. Kotsis K., Voulgari P.V., Tsifetaki N., Machado M.O., Carvalho A.F., Creed F., et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken) 2012, 64:1593-1601.
139. Kurizky P.S., Mota L.M. Sexual dysfunction in patients with psoriasis and psoriatic arthritis-a systematic review. Rev Bras Reumatol 2012, 52:943-948.
140. Cantini F., Nannini C., Niccoli L., Iannone F., Delogu G., Garlaschi G., et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015, 14:503-509.
141. Suzuki E., Mellins E.D., Gershwin M.E., Nestle F.O., Adamopoulos I.E. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014, 13:496-502.
142. Novelli L., Chimenti M.S., Chiricozzi A., Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev 2014, 13:64-69.
143. Olivieri I., D'Angelo S., Padula A., Leccese P., Nigro A., Palazzi C. Can we reduce the dosage of biologics in spondyloarthritis?. Autoimmun Rev 2013, 12:691-693.